NDAORALTABLET, CHEWABLEPriority Review
Approved
Oct 2016
Lifecycle
Peak
Competitive Pressure
30/100
Clinical Trials
5
Data completeness
3/8 — Basic
Priority Review
VERMOX (mebendazole) by Johnson & Johnson. Approved for anthelmintic [epc]. First approved in 2016.
Drug data last refreshed 20h ago
Mechanism of Action
Pharmacologic Class:
Anthelmintic
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Clinical Trials (5)
A Study to Assess the Efficacy and Safety of Mebendazole for the Treatment of Helminth Infections in Pediatric Participants
Started Dec 2014
295 enrolled
Helminth Infections
A Study to Assess the Effect of Food on the Bioavailability of Mebendazole From a Fast-Disintegrating Chewable Formulation of Mebendazole in Healthy Participants
Started Feb 2014
1 enrolled
Healthy
A Phase I Study of Mebendazole for the Treatment of Pediatric Gliomas
Started Oct 2013
36 enrolled
Pilomyxoid AstrocytomaPilocytic AstrocytomaGlioma, Astrocytic+9 more
A Safety Study of Mebendazole in Children 2 to 10 Years of Age
Started Feb 2010
397 enrolled
Healthy Volunteers
Study to Evaluate Efficacy and Safety of a Double Treatment Plan Using a Combination of Mebendazole and Quinfamide for Treating Intestinal Helminthiasis and Amebiasis in the Mexican Population
Started Oct 2005
100 enrolled
HelminthiasisAmoebiasis
Worked on VERMOX at Johnson & Johnson? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.